Takeover target Healthscope Ltd releases trading update

Healthscope Ltd (ASX:HSO) may reject another takeover approach.

| More on:

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

a woman

Shares in private hospital operator Healthscope Ltd (ASX: HSO) traded flat today after the takeover target provided a trading update where the group reaffirmed financial year 2019 guidance for hospital operating EBITDA growth of 10%.

For the quarter ending September 30 2019, Healthscope reported that it had achieved hospital operating EBITDA growth of 10.4%, compared to a 6.8% decline in the prior corresponding quarter.

The group also flagged that it opened its new Sydney's Northern Beaches hospital over the quarter that was built at an estimated cost of $840 million, with the company expecting to receive a "state capital payment of $400 million" relating to the build.

The group said the new hospital is expected to deliver "over $300 million in additional revenue and an EBITDA return on invested capital of at least 15%".

Healthscope is currently the subject of a $2.36 per share takeover offer from a consortium of capital market players including Australian Super and BGH, with the Healthscope board currently giving consideration to the offer.

As at October 31 the consortium seeking to takeover Healthscope owns 19.13% of the shares on issue.

In May 2018 it was also subject to a conditional $2.50 per share takeover to Canadian asset management and property development specialist Brookfield that Healthscope's board also rejected.

In 2015 and 2016 Healthscope's shares occasionally traded above $3 before a shock profit warning in October 2016 sent the share price into a nosedive. The problems were blamed on declining private healthcare affordability translating into lower hospital admissions.

Healthscope is largely focused on Australia unlike larger rival Ramsay Healthcare Ltd (ASX: RHC) that has continued to perform well in Australia, but struggled a little overseas in regions like the UK and France.

Healthscope's board maintains that the group is set to return to growth after labelling financial year 2018 a year of transition. In FY 2018 it paid a full year dividend of 6.7 cents, although it delivered basic earnings per share of just 4.4 cents. Total debt also stood at $1,946 million versus $156.8 million cash in hand.

Motley Fool contributor Yulia Mosaleva owns shares of Ramsay Health Care Limited. The Motley Fool Australia has recommended Ramsay Health Care Limited. We Fools may not all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors. The Motley Fool has a disclosure policy. This article contains general investment advice only (under AFSL 400691). Authorised by Scott Phillips.

More on Share Market News

a man weraing a suit sits nervously at his laptop computer biting into his clenched hand with nerves, and perhaps fear.
Share Fallers

Why Brightstar, EQ Resources, Novonix, and Pro Medicus shares are falling today

These shares are under pressure on hump day. But why?

Read more »

A happy family of four on holidays stand on a jetty and cheer.
Broker Notes

Down 40% in 2026, should you buy the big dip in Life360 shares?

A leading analyst offers his outlook for Life360 shares.

Read more »

Buy and sell on yellow paper with pins on them and several share price lines.
Broker Notes

Sell alert! Why this expert is calling time on Nuix and Brainchip shares

A leading analyst forecasts more pain to come for Brainchip and Nuix shares. But why?

Read more »

Ecstatic woman looking at her phone outside with her fist pumped.
Share Gainers

Why EOS, Humm, New Hope, and Sims shares are storming higher today

These shares are having a good session on hump day. But why?

Read more »

a man lies on his back on grass with his eyes shut and a contented look on his face as though he is dreaming
Broker Notes

With global populations ageing, are ResMed shares a good buy today?

A leading expert delivers his verdict on the outlook for ResMed shares.

Read more »

Wife and husband with a laptop on a sofa over the moon at good news.
Healthcare Shares

Why are Telix shares racing 8% higher today?

Telix shares are now 11% higher for the year-to-date.

Read more »

Magnifying glass on a rising interest rate graph.
Share Market News

Buying ASX shares or paying off a mortgage? Here's what the experts are saying about RBA interest rate hikes in 2026

Leading experts sound off on the RBA’s latest interest rate hike, and what investors and mortgage holders can expect next.

Read more »

Focused man entrepreneur with glasses working, looking at laptop screen thinking about something intently while sitting in the office.
Broker Notes

Buy, hold, sell: Clarity Pharmaceuticals, New Hope, and Orica shares

Brokers have been looking at these shares this week. Are they bullish?

Read more »